Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study

Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, 883, 10.1056/NEJM198310133091503 Tuxen, 1995, Tumour markers in the management of patients with ovarian cancer, Cancer Treat Rev, 21, 215, 10.1016/0305-7372(95)90002-0 Krebs, 1986, The role of CA 125 as a tumour marker in ovarian carcinoma, Obstet Gynecol, 67, 473 Van der Burg, 1990, The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer, Ann Oncol, 1, 301, 10.1093/oxfordjournals.annonc.a057754 Rustin, 1993, Tumour markers, Ann Oncol, 4, 71, 10.1093/annonc/4.suppl_4.S71 Allen, 1993, Advanced epithelial ovarian cancer: 1993 consensus statements, Ann Oncol, 4, 83, 10.1093/annonc/4.suppl_4.S83 Gard, 1994, An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma, Gynecol Oncol, 53, 283, 10.1006/gyno.1994.1135